Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 950 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Normal Cellular Metabolism Clear all
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Approved For Marketing No phase listed Expanded access

BMN 110 US Expanded Access Program

NCT01858103
View directory record Official record
Conditions
Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
Interventions
BMN 110
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Critical Periods of Exercise

NCT01041820
View directory record Official record
Conditions
Metabolism
Interventions
Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Years to 7 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease

NCT06283589
View directory record Official record
Conditions
Calciphylaxis
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Coral Springs, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Not applicable Interventional

Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

NCT06674980
View directory record Official record
Conditions
Pathologic Processes, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Disease, Diabetic Angiopathies, Vascular Diseases, Cardiovascular Diseases, Leg Ulcer, Skin Ulcer, Skin Diseases, Diabetes Complications, Diabetic Neuropathies, Foot Diseases, Diabetic Foot, Foot Ulcer, Diabetes Mellitus, Type 2, Ulcer, Foot Ulcer Unhealed
Interventions
Standard of Care - DFU, AM/Single - DFU, AM/Double - DFU, Standard of Care - VLU, AM/Single - VLU, AM/Double - VLU
Other
Lead sponsor
C5 Biomedical
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 21, 2026, 7:59 PM EDT
Completed No phase listed Observational

Risk Factors for Uterine Fibroids: A Case Control Study

NCT00339547
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Circadian Brown Adipose Tissue Metabolism

NCT02285270
View directory record Official record
Conditions
Healthy
Interventions
FDG PET/CT
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™

NCT01432561
View directory record Official record
Conditions
Cystinosis, Nephropathic Cystinosis
Interventions
Cysteamine bitartrate
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

NCT01730469
View directory record Official record
Conditions
Fabry Disease
Interventions
AT1001 150 mg
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Costa Mesa, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

NCT00003082
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
monoclonal antibody A27.15, monoclonal antibody E2.3
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

NCT04977388
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Stephen G. Kaler, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed No phase listed Observational

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

NCT00695279
View directory record Official record
Conditions
Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
Interventions
Venipuncture
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

NCT01261754
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc MIP 1404, 99mTc MIP 1405
Radiation
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 21, 2026, 7:59 PM EDT
Completed No phase listed Observational

Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors

NCT02006563
View directory record Official record
Conditions
Brain Tumor, Glioblastoma Multiforme
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 21, 2026, 7:59 PM EDT
Not yet recruiting Phase 2 Interventional

Effects of Meal Macronutrients on Postprandial Lipids

NCT07313787
View directory record Official record
Conditions
Nephrotic Syndrome, Lipodystrophy, Metabolic Syndrome, Healthy Volunteer, Diabetes, Metabolic Associated Steatotic Liver Disease
Interventions
High carb then high fat breakfast, High fat then high carb breakfast
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanisms for Activation of Beige Adipose Tissue in Humans

NCT04666636
View directory record Official record
Conditions
PreDiabetes
Interventions
Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells

NCT01828723
View directory record Official record
Conditions
Lipoatrophy, Aging, Wrinkles
Interventions
SVF
Biological
Lead sponsor
Antria
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Greensburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
View directory record Official record
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

NCT02071862
View directory record Official record
Conditions
Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
Interventions
CB-839, Pac-CB, CBE, CB-Erl, CBD, CB-Cabo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
San Francisco, California • Stanford, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 21, 2026, 7:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Metabolic Effects of Intermittent Fasting

NCT05722873
View directory record Official record
Conditions
Normal and Overweight Individuals at High-risk of Diabetes
Interventions
Fasting arm, Weight maintenance, Counseling
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Gene Therapy to Improve Wound Healing in Patients With Diabetes

NCT00065663
View directory record Official record
Conditions
Wounds and Injuries, Diabetes, Diabetic Foot Ulcers, Foot Wounds
Interventions
GAM501
Genetic
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Phoenix, Arizona • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2007 · Synced Oct 21, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Korean Translation and Validation of the K-HEPI in NYC

NCT05544578
View directory record Official record
Conditions
Disaster, Vulnerable Populations
Interventions
Nurses Taking On Readiness Measures (N- TORM)
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 21, 2026, 7:59 PM EDT
Terminated No phase listed Observational

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

NCT00260299
View directory record Official record
Conditions
Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary, Lipid Metabolism, Inborn Errors
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 21, 2026, 7:59 PM EDT